Can ctDNA predict outcomes in early phase trials?
Baseline and on-treatment changes in ctDNA may provide an early indication of response to experimental therapies
Challenges in cell-based immunotherapies create opportunities for progress
According to the 2023 ESMO Immuno-Oncology Awardee, Steven A. Rosenberg, the keys to progress are identifying the optimal characteristics of antitumour effector lymphocytes, cancer antigen identification and strategies for overcoming resistance mechanisms to enhance immune-cell function
Updated hallmarks of cancer guide treatment development
Old and emerging traits of cancer provide a common set of principles that may help research shape future progress
TIL therapy – an opportunity for a few centres?
Regulatory, practical and economic challenges are associated with implementing this personalised treatment on a larger scale, thus currently limiting its availability and accessibility to patients
Precision oncology – are we at an inflection point?
At Molecular Analysis for Precision Oncology (MAP) Congress 2023, international experts discuss the future of histology-agnostic drug development and clinical trial design
Exploiting knowledge of neutrophil protumour and antitumour phenotypes to treat cancer
Identifying the trigger that switches neutrophils from protumour to antitumour activity in the tumour microenvironment could open the door to new therapeutic options
The evolving landscape of rare tumour molecular characterisation
Continued collaboration to identify new molecular targets and treatments can build on existing success
Encouraging results validate PARP7 and TGFβ1 as potential targets for immunotherapy
Safety and biomarker status data of the PARP7 inhibitor RBN-2397 and the IgG4 monoclonal antibody SRK-181 presented at the ESMO TAT Congress 2023
Liquid biopsy moving to early cancer detection: is it still early times?
Despite the promises shown by some innovative technologies in the studies presented, they will not replace existing diagnostic modalities soon
Pathogenic variants in HRR genes can be a risk factor for anthracycline-induced cardiotoxicity
A study presented at ESMO Congress 2022 highlights the need to identify predictors of anticancer drug toxicity as more complex treatments become available